Prinomastat
Jump to navigation
Jump to search
Clinical data | |
---|---|
ATC code |
|
Pharmacokinetic data | |
Elimination half-life | 1–5 hours[1] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C18H21N3O5S2 |
Molar mass | 423.50 g·mol−1 |
3D model (JSmol) | |
| |
|
Prinomastat (code name AG-3340) is a matrix metalloproteinase (MMP) inhibitor with specific selectivity for MMPs 2, 3, 9, 13, and 14. Investigations have been carried out to determine whether the inhibition of these MMPs is able to block tumour metastasis by preventing MMP degradation of the extracellular matrix proteins and angiogenesis. Prinomastat underwent a Phase III trial to investigate its effectiveness against non-small cell lung cancer (NSCLC), in combination with gemcitabine chemotherapy. However, it was discovered that Prinomastat did not improve the outcome of chemotherapy in advanced non-small-cell lung cancer.[1][2]
References
- ^ a b Bissett D, O'Byrne KJ, von Pawel J, Gatzemeier U, Price A, Nicolson M, et al. (February 2005). "Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer". Journal of Clinical Oncology. 23 (4): 842–849. doi:10.1200/JCO.2005.03.170. PMID 15681529.
- ^ Hande KR, Collier M, Paradiso L, Stuart-Smith J, Dixon M, Clendeninn N, et al. (February 2004). "Phase I and pharmacokinetic study of prinomastat, a matrix metalloprotease inhibitor". Clinical Cancer Research. 10 (3): 909–915. doi:10.1158/1078-0432.CCR-0981-3. PMID 14871966.
Categories:
- Articles with short description
- Short description matches Wikidata
- Drugs not assigned an ATC code
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Experimental cancer drugs
- Hydroxamic acids
- Matrix metalloproteinase inhibitors
- Sulfonamides
- 4-Pyridyl compounds